Daratumumab and hyaluronidase-fihj

{
  "id": "MLC-T-ONC-012921",
  "term": "Daratumumab and hyaluronidase-fihj",
  "field": "Oncology and biomedicine",
  "definition": "A co-formulation composed of daratumumab, a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against the cell surface glycoprotein cluster of differentiation 38 (CD-38; CD38), and a recombinant form of human hyaluronidase (rHuPH20), with potential antineoplastic activity. Upon subcutaneous administration of daratumumab and hyaluronidase-fihj, daratumumab targets and binds to CD38 on certain CD38-expressing tumors, such as multiple myeloma (MM) and plasma cell leukemia. This binding induces direct apoptosis through Fc-mediated cross-linking and triggers immune-mediated tumor cell lysis through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP) immune responses. CD38, a transmembrane glycoprotein, is expressed in both hematopoietic and non-hematopoietic lineage cells. Hyaluronidase-fihj hydrolyzes and degrades the glycosaminoglycan hyaluronic acid (HA), thereby decreasing interstitial viscosity and enhancing penetration of daratumumab through the interstitial space. This facilitates the delivery of daratumumab to CD38-expressing tumor cells.",
  "synonyms": [
    "darzalex/rHuPH20",
    "daratumumab-rHuPH20",
    "daratumumab/rHuPH20 co-formulation",
    "DARA/rHuPH20",
    "daratumumab with rHuPH20",
    "HuMax-CD38-rHuPH20",
    "daratumumab + rHuPH20",
    "recombinant human hyaluronidase mixed with daratumumab",
    "DARA co-formulated with rHuPH20",
    "daratumumab and hyaluronidase",
    "daratumumab/hyaluronidase-fihj"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/daratumumab-and-hyaluronidase-fihj/"
}